IM To evaluate the clinical value of CA199 in diagnosing and differentiating the gastrointestinal tumors and in monitoring the patients treated surgically.METHODS Gastric cancer (n=70), colorectal cancer (n=90), pan...IM To evaluate the clinical value of CA199 in diagnosing and differentiating the gastrointestinal tumors and in monitoring the patients treated surgically.METHODS Gastric cancer (n=70), colorectal cancer (n=90), pancreatic cancer (n=7), esophageal cancer (n=10), benign disorder (n=30), and normal adults (n=111) as control were studied. Fasting blood samples were obtained from each patient and normal adult. The serum CA199 concentration was measured with radioimmunoassay.RESULTS The mean CA199 level in gastric cancer (17069kU/L±9145kU/L) and in colorectal cancer (8721kU/L±3955kU/L) was significantly higher than that in the control (11254kU/L±600kU/L). Compared with the normal adults, the CA199 level was much higher in pancreatic cancer patients (126658kU/L±52131kU/L) (P<001). However, the CA199 concentrations in nonrecurrent gastric (1263kU/L±362kU/L) and colorectal cancers (1414kU/L±326kU/L) and benign disorders (1423kU/L±260kU/L) were similar to the control. The differences were not statistically significant (P>005). The demarcation value of CA199 between the negative and positive was <310kU/L. The sensitivity of CA199 for gastric, colorectal, pancreatic and esophageal cancers and gastrointestinal benign disorders was 473%, 500%, 833%, 200% and 0%, respectively. The specificity of CA199 for digestive system malignant diseases was all 100%.展开更多
文摘IM To evaluate the clinical value of CA199 in diagnosing and differentiating the gastrointestinal tumors and in monitoring the patients treated surgically.METHODS Gastric cancer (n=70), colorectal cancer (n=90), pancreatic cancer (n=7), esophageal cancer (n=10), benign disorder (n=30), and normal adults (n=111) as control were studied. Fasting blood samples were obtained from each patient and normal adult. The serum CA199 concentration was measured with radioimmunoassay.RESULTS The mean CA199 level in gastric cancer (17069kU/L±9145kU/L) and in colorectal cancer (8721kU/L±3955kU/L) was significantly higher than that in the control (11254kU/L±600kU/L). Compared with the normal adults, the CA199 level was much higher in pancreatic cancer patients (126658kU/L±52131kU/L) (P<001). However, the CA199 concentrations in nonrecurrent gastric (1263kU/L±362kU/L) and colorectal cancers (1414kU/L±326kU/L) and benign disorders (1423kU/L±260kU/L) were similar to the control. The differences were not statistically significant (P>005). The demarcation value of CA199 between the negative and positive was <310kU/L. The sensitivity of CA199 for gastric, colorectal, pancreatic and esophageal cancers and gastrointestinal benign disorders was 473%, 500%, 833%, 200% and 0%, respectively. The specificity of CA199 for digestive system malignant diseases was all 100%.
